10A-1091104
TW, PCT pending
Abnormal HGFR activation in cancer is associated with poor prognosis. Abnormally activated HGFR triggers tumor growth, the formation of new blood vessels that provide nutrition to the tumor (angiogenesis), and the spread of cancer to other organs (metastasis). Wnt/β-catenin signals control tissue regeneration in adult bone marrow, skin and intestines. If there is an abnormality, the cause also affects the occurrence of cancer. In cells overexpressing EpCAM, we found that the addition of EpEX activates the HGFR and Wnt/β-catenin signaling pathways. If hEpAb2-6 is added, it can inhibit HGFR and Wnt/β-catenin signaling pathway. Among them, after hEpAb2-6 inhibits HGFR phosphorylation, it also reduces the phosphorylation of TACE and Presenilin 2. When inhibiting Wnt/β-catenin, it also can reduce the stemness of cancer cells and induce cell apoptosis.
Discover a new signaling pathway mechanism for EpCAM. In the future, antibodies or small molecule drugs can be developed to block EpCAM signal transduction.
- 1. EpAb2-6 inhibits HGFR and β-catenin signaling pathway.
- 2. Develop antibodies or small molecule drugs to block EpCAM signal transmission to increase the efficacy of HGFR and β-catenin inhibitors.
Han-Chung Wu
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Signaling of EpCAM, HGFR, and Wnt/β-catenin